tiprankstipranks
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT

Rocket Pharmaceuticals Stock Analysis & Ratings

RCKT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$7.57 - $49.66
Previous Close$10.78
Volume3.00
Average Volume (3M)536.28K
Market Cap$709.73M
P/E Ratio-4.0
Beta1.92
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-2.68


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

RCKT FAQ

What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $7.57 and its highest was $49.66 in the past 12 months.
    What is Rocket Pharmaceuticals’s market cap?
    Rocket Pharmaceuticals’s market cap is $709.73M.
      What is Rocket Pharmaceuticals’s price target?
      The average price target for Rocket Pharmaceuticals is $56.20. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $65.00 ,the lowest forecast is $30.00. The average price target represents 421.34% Increase from the current price of $10.78.
        What do analysts say about Rocket Pharmaceuticals?
        Rocket Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
          When is Rocket Pharmaceuticals’s upcoming earnings report date?
          Rocket Pharmaceuticals’s upcoming earnings report date is Aug 10, 2022 which is in 84 days.
            How were Rocket Pharmaceuticals’s earnings last quarter?
            Rocket Pharmaceuticals released its earnings results on May 05, 2022. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$0.711 by $0.041.
              Is Rocket Pharmaceuticals overvalued?
              According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
                Does Rocket Pharmaceuticals pay dividends?
                Rocket Pharmaceuticals does not currently pay dividends.
                What is Rocket Pharmaceuticals’s EPS estimate?
                Rocket Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Rocket Pharmaceuticals have?
                Rocket Pharmaceuticals has 65,840,000 shares outstanding.
                  What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
                  Rocket Pharmaceuticals reported an EPS of -$0.67 in its last earnings report, beating expectations of -$0.711. Following the earnings report the stock price went down -5.5%.
                    Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
                    Among the largest hedge funds holding Rocket Pharmaceuticals’s share is Maverick Capital ltd. It holds Rocket Pharmaceuticals’s shares valued at 34M.

                      ---

                      Rocket Pharmaceuticals Stock Analysis

                      The Rocket Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Rocket Pharmaceuticals

                      Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Ocular Therapeutix
                      EyePoint Pharmaceuticals
                      Pfizer
                      Regeneron
                      Aerie Pharma

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis